The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients has reported FYDec16 results with total income up to €18.2m from €11.6m representing 57% growth. Within that revenue was €17.9m. Revenue growth driven by both organic activity and strategic acquisitions has seen compound annual growth in revenues of 106% since 2013. Managing such growth and la
22 Mar 2017
Strong growth continues. Measures in place to optimise utilisation and improve margins
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong growth continues. Measures in place to optimise utilisation and improve margins
hVIVO plc (HVO:LON) | 28.2 0.2 2.7% | Mkt Cap: 192.2m
- Published:
22 Mar 2017 -
Author:
Derren Nathan -
Pages:
6
The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients has reported FYDec16 results with total income up to €18.2m from €11.6m representing 57% growth. Within that revenue was €17.9m. Revenue growth driven by both organic activity and strategic acquisitions has seen compound annual growth in revenues of 106% since 2013. Managing such growth and la